Kinnevik AB
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KNKBF research report →
Price Chart
About the company
Kinnevik AB, previously Investment AB Kinnevik, operates as a venture capital firm dedicated to growth capital investments. While its primary focus is on digital consumer services, education, communications, e-commerce and online marketplaces, entertainment, healthcare, and financial services, the company remains open to opportunities across various other sectors. Its investment footprint is global, with a notable concentration in Europe, particularly the Nordic region, alongside Latin America, Asia, Australia, Africa, and North America.
- CEO
- Georgi Ganev
- IPO
- 2010
- Employees
- 46
- HQ
- Stockholm, SE
Get TickerSpark's AI analysis on KNKBF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.13B
- P/E
- -2.34
- Fwd P/E
- 2.48
- PEG
- -0.00
- P/S
- -2.64
- P/B
- 0.61
- EV/EBITDA
- -1.97
- Div Yield
- 0.00%
- Gross Margin
- 100.94%
- Op Margin
- 145.08%
- Net Margin
- 128.93%
- ROE
- -25.02%
- ROIC
- -24.28%
Latest fiscal year · YoY change
- Revenue
- $947.00M-73.3%
- Gross Profit
- $947.00M-73.3%
- Op Income
- $-4,903,000,000
- Net Income
- $-4,766,000,000+75.6%
- EPS
- $-16.96+75.7%
- OCF Growth
- -81.1%
- FCF Growth
- -81.1%
- 52W High
- $13.56
- 52W Low
- $8.36
- 50D MA
- $10.00
- 200D MA
- $10.35
- Beta
- 1.25
- RSI (14)
- 54
- Avg Volume
- 442
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Kinnevik reported a stable Q3 with NAV up 1% as portfolio growth and a weaker krona offset valuation pressure from updated forward assumptions and climate tech write-downs.· October 15, 2026
- NAV ended the quarter at NOK 29.8 billion, or SEK 108 per share, up 1% since Q2.
- The company invested SEK 165 million and divested DKK 183 million, ending with SEK 7.4 billion of net cash.
- Unlisted companies delivered a 1% total return, while the Kinnevik B share delivered a 19% total shareholder return in the quarter.
- Valuation pressure came mainly from lower forward growth assumptions in some larger holdings and a zeroing of Climate Tech Holdings, mainly Stegra.
- Management is shifting toward a more focused portfolio, fewer larger profitable holdings, tighter capital discipline, and lower costs by 2027.
Kinnevik said net asset value was NOK 29.8 billion at quarter-end, equal to SEK 108 per share, up 1% from Q2. It invested SEK 165 million and divested DKK 183 million, finishing with a net cash position of SEK 7.4 billion. The private portfolio value rose 1% to SEK 22.5 billion; health and bio added SEK 400 million, emerging companies added SEK 300 million, and currency added 3% to portfolio value. On the negative side, software and other investments each declined by around SEK 200 million, and Climate Tech Holdings was written down, mainly Stegra, now held at zero value. For the largest holdings, Spring Health and Perk were broadly unchanged, while Enveda and Tandem Health rose 30% to 35% after new rounds; Cityblock was broadly flat despite the Homeward acquisition and new financing. The company did not provide EPS, revenue, gross margin, or formal next-quarter/full-year financial guidance in the prepared remarks.
Helena Saxon emphasized that the quarter was about getting to know the business, the team, and stakeholders, and said she is struck by the strength of the portfolio and the interest in Kinnevik’s future. Strategically, she said Kinnevik will build a more focused portfolio, concentrate on fewer larger profitable holdings in later growth stages, and allocate capital only to growth companies with a clear path to profitability. Her tone was constructive but disciplined: she repeatedly stressed financial discipline, transparency, and the need to rebuild credibility through consistent delivery.
Caspar Sjöstrand focused on valuation and peer comparisons, saying the portfolio was up 1% in the quarter and that valuation changes reflected calibration to subsector peers rather than any change in methodology. He said Spring Health has forward revenues of around $1 billion pro forma for Alma, Perk is approaching $400 million in annualized revenue after growing 48% in 2025, and the combined health and bio and software portfolios grew revenues by over 30% over the last 12 months, versus peers at roughly 20% to 25%. He also said EBITDA margins remain around breakeven in health and bio and still negative in software, though the combined EBITDA margin is up 7 percentage points so far this year. Currency helped as around 75% of the private portfolio is in U.S. dollars and about a quarter in euros, with the weaker krona adding 3% to portfolio value.
Analysts pressed management on why valuations were being marked down despite strong operating growth, especially for Spring Health, Muse, Pleo, Cityblock, and Oviva. Caspar repeatedly answered that there was no change in valuation methodology, that some subsector peers were weaker, and that the company calibrates values based on growth, profitability, and scale rather than mirroring peer moves one-for-one. On Cityblock, he said the all-stock Homeward acquisition diluted ownership but the deal should create synergies over time, so they did not re-rate the name on day one. On capital allocation, management declined to set a timetable for new investments or deeper portfolio pruning, saying the focus is on building the right pipeline and preserving financial flexibility during the transition; Helena also said they are deliberately taking a smaller share of Enveda because existing exposure is already sufficient.
The core positive message is that underlying portfolio companies are still growing strongly, with several businesses continuing to expand at high rates and improved margins. Kinnevik also has a strong balance sheet, SEK 7.4 billion of net cash, and management sounded confident that the company can create value through a more focused portfolio and disciplined capital deployment.
The main risk flagged on the call is that valuations are not keeping pace with operating growth because of lower forward growth assumptions, weaker peer multiples, and the write-down of Climate Tech Holdings. Management also acknowledged that some businesses, including software and health and bio, still have margins below mature peers, while certain holdings face specific issues such as reimbursement changes at Oviva and market weakness in transaction software and value-based care peers.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 84.4%
- Shares Outstanding
- 281.18M
- Float Shares
- 237.26M
Our KNKBF coverage
Recent articles, reports, and earnings notes.
No research on KNKBF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KNKBF report →